Home
Duchenne
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
Search
About Us
Contact
APPs
Privacy Policy
type here...
Search
Instagram
Facebook
Twitter
Bluesky
Home
Duchenne
Duchenne MD
What is Duchenne?
Genetic Causes
Creatine Kinase (CK)
Genetic Testing
Prenatal Testing
Becker MD
DMD vs BMD
NSAA Assessment
Genetic
Genetic Counseling
Dystrophin Gene
Genetic Variants
Exon Deletion
Duchenne Carriers
Nucleotides in DMD
Isoforms in DMD
What is Exon Skipping
Care Guidelines
Newly Diagnosed
Neuromuscular Team
Respiratory Devices
BiPAP Machine
Ankle Foot Orthosis
Rhabdomyolysis
Power Wheelchair
Traveling with DMD
Health Guidelines
Psychological Support in DMD
Nutrition in DMD
Nutraceuticals
Respiratory Health
Dental Health
Surgery & Anesthesia
Swallowing Difficulty
Steroids (Cortisone)
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
WhatsAPP
Home
Tags
RGX-202
RGX-202
Editorials
7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026
Press Releases
REGENXBIO Completes RGX-202 Confirmatory Study for Duchenne Muscular Dystrophy
Press Releases
RGX-202 Duchenne Gene Therapy Shows NSAA Improvement and Microdystrophin Expression — But Important Biomarker Data Missing
Editorials
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
Press Releases
Regenxbio Reports New Positive Interim Data From Phase 1/2 Affinity Duchenne Trial Of Rgx-202
Editorials
Compared to Its Million-Dollar Price Tag, How Much Does Elevidys Gene Therapy Improve the Condition of Children With DMD?
Press Releases
REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
Research
RGX-202 Gene Therapy Phase 3 Clinical Trial Begins
Press Releases
New Positive Functional Data From The RGX-202 Affinity Duchenne® Trial Phase 1/2 Reported By Regenxbio
Regenxbio RGX-202
1
2
Page 1 of 2
Popular
Frequently Asked Questions About Elevidys Used for DMD
Can Ekinci
-
August 21, 2026
Must Read
Editorials
CRISPR GuideX Tool: hfCas12Max in CRISPR-Based Therapeutics
Care Guidelines
Breathing Exercises in Duchenne Muscular Dystrophy: Respiratory Therapy, Pulmonary Care & Lung Support
Research
BioMarin Launches BMN 351 Exon 51 Skipping Therapy Phase 2 Clinical Trial for Duchenne Muscular Dystrophy
EN
AR
ZH
FR
DE
HI
RU
PT
ES
TR